Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Read More Pharma Industry News What clinicians and regulators may question as GLP-1 therapies move into consumer health platforms Discover how Hims & Hers and Novo Nordisk are reshaping GLP-1 access and what it means for pricing, regulation, and long-term care models. bySoujanya RaviMarch 29, 2026